IBD1
MCID: INF071
MIFTS: 67

Inflammatory Bowel Disease 1 (IBD1)

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Inflammatory Bowel Disease 1

MalaCards integrated aliases for Inflammatory Bowel Disease 1:

Name: Inflammatory Bowel Disease 1 56 73
Inflammatory Bowel Disease 1 12 73 29 6 15
Crohn Disease 73 36 6 71
Crohn Disease-Associated Growth Failure 56 73 13
Ibd1 56 12 73
Crohn Disease-Associated Growth Failure, Susceptibility to 29 6
Inflammatory Bowel Disease 1, Crohn Disease 56 29
Ulcerative Colitis 73 71
Regional Enteritis 73 71
Bowel Disease, Inflammatory, Type 1 39

Characteristics:

OMIM:

56
Inheritance:
multifactorial

Miscellaneous:
genetic heterogeneity
5-10% of patients have a first degree relative with ibd (crohn or ulcerative colitis)
35% of cases involve ileum only (ileitis), 45% of cases involve ileum and colon (ileocolitis), 20% of cases involve colon alone - rectum spared (granulomatous colitis)


HPO:

31
inflammatory bowel disease 1:
Inheritance multifactorial inheritance heterogeneous


Classifications:



External Ids:

Disease Ontology 12 DOID:0110892
OMIM 56 266600
OMIM Phenotypic Series 56 PS266600
KEGG 36 H00286
UMLS 71 C0009324 C0010346 C0678202

Summaries for Inflammatory Bowel Disease 1

UniProtKB/Swiss-Prot : 73 Inflammatory bowel disease 1: A chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.

MalaCards based summary : Inflammatory Bowel Disease 1, also known as inflammatory bowel disease 1, is related to cholangitis, primary sclerosing and inflammatory bowel disease 19, and has symptoms including nausea and vomiting, abdominal pain and constipation. An important gene associated with Inflammatory Bowel Disease 1 is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are NOD-like receptor signaling pathway and Cytokine-cytokine receptor interaction. The drugs Tocopherol and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include colon, bone and small intestine, and related phenotypes are weight loss and abdominal pain

Disease Ontology : 12 An inflammatory bowel disease that has material basis in mutations in the NOD2 gene on chromosome 16q12.1.

KEGG : 36 Crohn disease is a chronic, relapsing inflammatory bowel disease characterized by granulomatous inflammation, primarily localized to the terminal ileum. Most patients have involvement of the small intestine, but the other area of gastrointestinal tract may also be affected. In Western populations, over 50% of patients possess NOD2 mutations. Evidence exists that the NOD2 polymorphisms impair NF-kappaB activation and cytokine secretion in response to its ligand. The pathogenesis of Crohn's disease is also attributed to intestinal bacteria that may initiate mucosal inflammation in genetically susceptible individuals. Additional genes associated with the disease are recently being identified.

More information from OMIM: 266600 PS266600

Related Diseases for Inflammatory Bowel Disease 1

Diseases in the Inflammatory Bowel Disease family:

Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 3
Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 5
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 6
Inflammatory Bowel Disease 4 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 12
Inflammatory Bowel Disease 13 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 15 Inflammatory Bowel Disease 16
Inflammatory Bowel Disease 17 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 19 Inflammatory Bowel Disease 20
Inflammatory Bowel Disease 21 Inflammatory Bowel Disease 22
Inflammatory Bowel Disease 23 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Autosomal Recessive Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 28, Autosomal Recessive
Inflammatory Bowel Disease 29 Inflammatory Bowel Disease 28
Inflammatory Bowel Disease 25 Rare Inflammatory Bowel Disease

Diseases related to Inflammatory Bowel Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1270)
# Related Disease Score Top Affiliating Genes
1 cholangitis, primary sclerosing 33.3 NOD2 IL6 CCR6
2 inflammatory bowel disease 19 33.3 TNFSF15 NOD2 IRGM
3 chemical colitis 33.0 NOD2 IL6
4 ileitis 31.7 NOD2 IL6 CCR6 ATG16L1
5 diverticulitis 31.4 TNFSF15 IL6 CCR6
6 spondylitis 31.4 NOD2 IL6 IL23R CCR6
7 spondyloarthropathy 1 31.3 NOD2 IL23R CCR6
8 ileocolitis 31.1 PLA2G4F NOD2 ATG16L1
9 celiac disease 1 31.0 NOD2 IL6 IL23R CCR6 ATG16L1
10 psoriatic arthritis 30.9 NOD2 IL6 IL23R CCR6
11 crohn's colitis 30.9 NOD2 CCR6 ATG16L1
12 bacterial infectious disease 30.8 NOD2 NOD1 IL6 CCR6
13 iritis 30.8 NOD2 IL6 CCR6
14 inflammatory bowel disease 2 30.8 NOD2 ATG16L1
15 inflammatory bowel disease 3 30.7 NOD2 IL23R
16 perinatal necrotizing enterocolitis 30.6 NOD2 IL6 CCR6
17 blau syndrome 30.5 RIPK2 NOD2 NOD1
18 panuveitis 30.4 IL6 IL23R CCR6
19 aspergillosis 30.3 NOD2 IL6 CCR6
20 inflammatory bowel disease 9 30.3 PLA2G4F NOD2 CCR6
21 inflammatory bowel disease 6 30.3 NOD2 IL23R ATG16L1
22 tracheitis 30.2 SLC22A4 IL6
23 testicular disease 30.1 TNFSF15 RIPK2 NOD2 IL6 CCR6
24 tenosynovitis 30.0 NOD2 IL6
25 behcet syndrome 30.0 NOD2 IL6 IL23R CCR6
26 ulcerative colitis 30.0 TNFSF15 NOD2 IRGM IL6 IL23R CCR6
27 blastomycosis 29.9 IL6 CCR6
28 leprosy 3 29.9 TNFSF15 RIPK2 NOD2 IRGM IL6 IL23R
29 inflammatory bowel disease 5 29.8 TNFSF15 SLC22A5 SLC22A4 NOD2 IRGM IL23R
30 colitis 29.8 NOD2 NOD1 IRGM IL6 IL23R CCR6
31 inflammatory bowel disease 29.0 TNFSF15 SLC22A5 SLC22A4 RIPK2 NOD2 NOD1
32 crohn's disease 29.0 TNFSF15 SLC22A5 SLC22A4 NOD2 NOD1 IRGM
33 pediatric ulcerative colitis 12.6
34 ulcerative proctitis 11.9
35 colorectal cancer 11.8
36 irritable bowel syndrome 11.8
37 pouchitis 11.8
38 inflammatory bowel disease 17 11.7
39 inflammatory bowel disease 10 11.7
40 inflammatory bowel disease 25, autosomal recessive 11.7
41 pyoderma gangrenosum 11.7
42 colonic disease 11.7
43 bile duct cancer 11.6
44 hemorrhoid 11.6
45 colorectal cancer 10 11.6
46 inflammatory bowel disease 14 11.4
47 inflammatory bowel disease 28, autosomal recessive 11.4
48 inflammatory bowel disease 29 11.3
49 polyposis syndrome, hereditary mixed, 1 11.3
50 colorectal cancer 1 11.3

Comorbidity relations with Inflammatory Bowel Disease 1 via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Crohn's Disease Deficiency Anemia
Esophagitis Intestinal Obstruction
Iron Deficiency Anemia Osteoporosis
Paralytic Ileus Protein-Energy Malnutrition
Ulcerative Colitis

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease 1:



Diseases related to Inflammatory Bowel Disease   1

Symptoms & Phenotypes for Inflammatory Bowel Disease 1

Human phenotypes related to Inflammatory Bowel Disease 1:

31 (show all 7)
# Description HPO Frequency HPO Source Accession
1 weight loss 31 HP:0001824
2 abdominal pain 31 HP:0002027
3 growth delay 31 HP:0001510
4 intestinal obstruction 31 HP:0005214
5 diarrhea 31 HP:0002014
6 recurrent aphthous stomatitis 31 HP:0011107
7 ulcerative colitis 31 HP:0100279

Symptoms via clinical synopsis from OMIM:

56
Growth Weight:
weight loss

Head And Neck Mouth:
aphthous ulcers (lips, gingiva, buccal mucosa)

Abdomen Gastrointestinal:
abdominal pain
diarrhea
aphthous ulcers
bowel obstruction
strictures
more

Clinical features from OMIM:

266600

UMLS symptoms related to Inflammatory Bowel Disease 1:


nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Inflammatory Bowel Disease 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.17 ATG16L1 IL23R IL6 NOD2 PRKCQ RIPK2

Drugs & Therapeutics for Inflammatory Bowel Disease 1

Drugs for Inflammatory Bowel Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 468)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Zinc Approved, Investigational Phase 4 7440-66-6 32051
5
Clarithromycin Approved Phase 4 81103-11-9 84029
6
Copper Approved, Investigational Phase 4 7440-50-8 27099
7
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
8
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
9
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
10
Prucalopride Approved Phase 4 179474-81-8
11
Metronidazole Approved Phase 4 443-48-1 4173
12
Azithromycin Approved Phase 4 83905-01-5 447043 55185
13
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
14
Nicotine Approved Phase 4 54-11-5 942 89594
15
carbamide peroxide Approved Phase 4 124-43-6
16
Magnesium citrate Approved Phase 4 3344-18-1
17
Ondansetron Approved Phase 4 99614-02-5 4595
18
Vancomycin Approved Phase 4 1404-90-6 14969 441141
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
21
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
22
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
23
Racepinephrine Approved Phase 4 329-65-7 838
24
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
25
Ustekinumab Approved, Investigational Phase 4 815610-63-0
26
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
27
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
28
Caffeine Approved Phase 4 58-08-2 2519
29
Tofacitinib Approved, Investigational Phase 4 477600-75-2
30
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
31
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
32
Losartan Approved Phase 4 114798-26-4 3961
33
Certolizumab pegol Approved Phase 4 428863-50-7
34
tannic acid Approved Phase 4 1401-55-4
35
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
36
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
37
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
38
leucovorin Approved Phase 4 58-05-9 6006 143
39
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
40
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
41
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
42
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
43
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
44 Tocotrienol Investigational Phase 4 6829-55-6
45 Tocotrienols Phase 4
46 Tocopherols Phase 4
47 Antifungal Agents Phase 4
48 Hydrocortisone-17-butyrate Phase 4
49 Cytochrome P-450 CYP3A Inhibitors Phase 4
50 Copper Supplement Phase 4

Interventional clinical trials:

(show top 50) (show all 2148)
# Name Status NCT ID Phase Drugs
1 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
2 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
3 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial Unknown status NCT02770040 Phase 4 Infliximab
4 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial Unknown status NCT02962245 Phase 4 berberine;regular treatment
5 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
6 Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. Unknown status NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
7 Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis Unknown status NCT02412085 Phase 4 Golimumab
8 A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
9 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
10 Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi) Unknown status NCT02186886 Phase 4 Golimumab
11 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
12 Comparison Between Two Therapeutic Strategies for the Maintenance of Clinical and Endoscopic Remission in Patients With Ulcerative Colitis Treated by Infliximab Unknown status NCT03151525 Phase 4 Azathioprine;Infliximab
13 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
14 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
15 Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO) Unknown status NCT02597829 Phase 4 Certolizumab Pegol
16 A Randomized, Controlled, Single-blind Study of Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
17 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
18 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
19 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
20 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
21 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
22 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
23 Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy Unknown status NCT01024647 Phase 4
24 Efficacy and Safety of Sirolimus in the Treatment of Crohn's Disease With Stenosis Unknown status NCT02675153 Phase 4 Sirolimus;5-ASA, Prednisone, Azathioprine or Remicade
25 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study Unknown status NCT01817426 Phase 4 Infliximab
26 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
27 Phase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
28 Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
29 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
30 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
31 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
32 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
33 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
34 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Completed NCT01804166 Phase 4 Infliximab;Golimumab
35 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
36 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
37 Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
38 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
39 Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies Completed NCT01481142 Phase 4
40 A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
41 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
42 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
43 A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
44 Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis Completed NCT02092285 Phase 4 Golimumab
45 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
46 Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients Completed NCT01408810 Phase 4 Infliximab
47 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
48 Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease Completed NCT00114465 Phase 4 VSL#3
49 Test Treat Strategy to Prevent Ulcerative Colitis Relapse Completed NCT00652145 Phase 4 mesalamine
50 Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial Completed NCT02256462 Phase 4 Adalimumab

Search NIH Clinical Center for Inflammatory Bowel Disease 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


aminosalicylic acid
Azathioprine
balsalazide
Balsalazide disodium
Cholecalciferol
Hydrocortisone
hydrocortisone acetate
HYDROCORTISONE ACETATE PWDR
HYDROCORTISONE ACETONIDE
Hydrocortisone butyrate
hydrocortisone cypionate
hydrocortisone probutate
HYDROCORTISONE PWDR
Hydrocortisone sodium phosphate
Hydrocortisone sodium succinate
hydrocortisone valerate
HYDROCORTISONE,NONSTERILE PWDR
mesalamine
natalizumab
nicotine polacrilex
olsalazine
Olsalazine sodium
Opium
OPIUM ALKALOIDS HYDROCHLORIDE
OPIUM, POWDERED
paregoric
Psyllium
PSYLLIUM HYDROCOLLOID
Sulfasalazine
Thalidomide

Genetic Tests for Inflammatory Bowel Disease 1

Genetic tests related to Inflammatory Bowel Disease 1:

# Genetic test Affiliating Genes
1 Inflammatory Bowel Disease 1 29 IL6 NOD2
2 Inflammatory Bowel Disease 1, Crohn Disease 29
3 Crohn Disease-Associated Growth Failure, Susceptibility to 29

Anatomical Context for Inflammatory Bowel Disease 1

MalaCards organs/tissues related to Inflammatory Bowel Disease 1:

40
Colon, Bone, Small Intestine, T Cells, Testes, Skin, Brain

Publications for Inflammatory Bowel Disease 1

Articles related to Inflammatory Bowel Disease 1:

(show top 50) (show all 156)
# Title Authors PMID Year
1
Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. 6 56
16150725 2005
2
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. 6 56
11385576 2001
3
Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. 56
31853061 2020
4
Somatic inflammatory gene mutations in human ulcerative colitis epithelium. 56
31853059 2020
5
Colonic epithelial cell diversity in health and inflammatory bowel disease. 56
30814735 2019
6
Fine-mapping inflammatory bowel disease loci to single-variant resolution. 56
28658209 2017
7
Ubiquitin Ligase TRIM62 Regulates CARD9-Mediated Anti-fungal Immunity and Intestinal Inflammation. 56
26488816 2015
8
NOD2-associated autoinflammatory disease: a large cohort study. 6
26070941 2015
9
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. 56
25785968 2015
10
Paneth cells as a site of origin for intestinal inflammation. 56
24089213 2013
11
TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. 56
23566200 2013
12
Dermatitis as a characteristic phenotype of a new autoinflammatory disease associated with NOD2 mutations. 6
23102769 2013
13
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. 56
23128233 2012
14
Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. 56
22674328 2012
15
Dissecting the genetics of complex inheritance: linkage disequilibrium mapping provides insight into Crohn disease. 56
22152681 2011
16
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. 56
21983784 2011
17
Genetics and pathogenesis of inflammatory bowel disease. 56
21677747 2011
18
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. 56
21151126 2011
19
A new category of autoinflammatory disease associated with NOD2 gene mutations. 6
21914217 2011
20
Analysis of SNPs with an effect on gene expression identifies UBE2L3 and BCL3 as potential new risk genes for Crohn's disease. 56
20601676 2010
21
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. 56
20570966 2010
22
Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. 56
20176734 2010
23
Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). 56
20228798 2010
24
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. 56
20228799 2010
25
NOD2-associated diseases: Bridging innate immunity and autoinflammation. 6
19467619 2010
26
A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. 56
19915573 2009
27
Inflammatory bowel disease. 56
19923578 2009
28
rs224136 on chromosome 10q21.1 and variants in PHOX2B, NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn's disease in the German population. 56
19262523 2009
29
Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. 56
19249008 2009
30
Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. 56
19174780 2009
31
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. 56
19122664 2009
32
Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. 56
19068216 2009
33
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. 56
19098911 2009
34
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. 56
18836448 2008
35
Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. 56
18422560 2008
36
Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. 56
18759272 2008
37
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. 56
18587394 2008
38
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. 56
18438405 2008
39
Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. 56
18439550 2008
40
An SNP linkage scan identifies significant Crohn's disease loci on chromosomes 13q13.3 and, in Jewish families, on 1p35.2 and 3q29. 56
18246054 2008
41
New links to the pathogenesis of Crohn disease provided by genome-wide association scans. 56
17968351 2008
42
The genetics of inflammatory bowel disease. 56
17919503 2007
43
Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. 56
17804789 2007
44
Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals. 6
17623760 2007
45
Increased expression and activation of IL-12-induced Stat4 signaling in the mucosa of ulcerative colitis patients. 56
18048021 2007
46
Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. 56
17554261 2007
47
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. 56
17554300 2007
48
CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. 56
17525800 2007
49
Inflammatory bowel disease: cause and immunobiology. 56
17499605 2007
50
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. 56
17435756 2007

Variations for Inflammatory Bowel Disease 1

ClinVar genetic disease variations for Inflammatory Bowel Disease 1:

6 (show top 50) (show all 279) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HSPA1L NM_005527.4(HSPA1L):c.1673A>C (p.Glu558Ala)SNV association 372131 rs2227955 6:31778077-31778077 6:31810300-31810300
2 HSPA1L NM_005527.4(HSPA1L):c.802G>A (p.Ala268Thr)SNV association 372132 rs34620296 6:31778948-31778948 6:31811171-31811171
3 HSPA1L NM_005527.4(HSPA1L):c.800C>T (p.Thr267Ile)SNV association 372133 rs139868987 6:31778950-31778950 6:31811173-31811173
4 HSPA1L NM_005527.4(HSPA1L):c.515_517del (p.Leu172del)deletion association 372135 rs750447828 6:31779233-31779235 6:31811456-31811458
5 HSPA1L NM_005527.4(HSPA1L):c.229G>A (p.Gly77Ser)SNV association 372134 rs368138379 6:31779521-31779521 6:31811744-31811744
6 NOD2 NM_022162.3(NOD2):c.1538T>C (p.Met513Thr)SNV Pathogenic 97834 rs104895473 16:50745360-50745360 16:50711449-50711449
7 PRKCQ NM_006257.5(PRKCQ):c.989C>T (p.Pro330Leu)SNV Pathogenic 586982 rs2236379 10:6527143-6527143 10:6485181-6485181
8 NOD2 NM_022162.3(NOD2):c.1720C>T (p.Gln574Ter)SNV Pathogenic 634817 rs1264862631 16:50745542-50745542 16:50711631-50711631
9 NOD2 NM_022162.3(NOD2):c.1001G>A (p.Arg334Gln)SNV Pathogenic 4694 rs104895461 16:50744823-50744823 16:50710912-50710912
10 NOD2 NM_022162.3(NOD2):c.1000C>T (p.Arg334Trp)SNV Pathogenic 4696 rs104895462 16:50744822-50744822 16:50710911-50710911
11 NOD2 NM_022162.3(NOD2):c.1147G>A (p.Glu383Lys)SNV Pathogenic 4701 rs104895477 16:50744969-50744969 16:50711058-50711058
12 IL6 IL6, -174G-CSNV risk factor 14718
13 NOD2 NM_022162.3(NOD2):c.3019dup (p.Leu1007fs)duplication risk factor 4691 rs2066847 16:50763778-50763779 16:50729867-50729868
14 NOD2 NM_022162.3(NOD2):c.2722G>C (p.Gly908Arg)SNV risk factor 4692 rs2066845 16:50756540-50756540 16:50722629-50722629
15 NOD2 NM_022162.3(NOD2):c.2104C>T (p.Arg702Trp)SNV risk factor 4693 rs2066844 16:50745926-50745926 16:50712015-50712015
16 NOD2 NM_022162.3(NOD2):c.2555A>G (p.Asn852Ser)SNV risk factor 97856 rs104895467 16:50750810-50750810 16:50716899-50716899
17 NOD2 NM_022162.3(NOD2):c.2377G>A (p.Val793Met)SNV Conflicting interpretations of pathogenicity 97851 rs104895444 16:50746199-50746199 16:50712288-50712288
18 NOD2 NM_022162.3(NOD2):c.2138G>A (p.Arg713His)SNV Conflicting interpretations of pathogenicity 97844 rs104895483 16:50745960-50745960 16:50712049-50712049
19 NOD2 NM_022162.3(NOD2):c.2332G>A (p.Glu778Lys)SNV Conflicting interpretations of pathogenicity 97848 rs104895443 16:50746154-50746154 16:50712243-50712243
20 NOD2 NM_022162.3(NOD2):c.2371C>T (p.Arg791Trp)SNV Conflicting interpretations of pathogenicity 97849 rs104895484 16:50746193-50746193 16:50712282-50712282
21 NOD2 NM_022162.3(NOD2):c.1509G>A (p.Glu503=)SNV Conflicting interpretations of pathogenicity 97833 rs104895434 16:50745331-50745331 16:50711420-50711420
22 NOD2 NM_022162.3(NOD2):c.1281G>A (p.Pro427=)SNV Conflicting interpretations of pathogenicity 97825 rs104895430 16:50745103-50745103 16:50711192-50711192
23 NOD2 NM_022162.3(NOD2):c.1292C>T (p.Ser431Leu)SNV Conflicting interpretations of pathogenicity 97826 rs104895431 16:50745114-50745114 16:50711203-50711203
24 NOD2 NM_022162.3(NOD2):c.1321G>A (p.Glu441Lys)SNV Conflicting interpretations of pathogenicity 97827 rs104895432 16:50745143-50745143 16:50711232-50711232
25 NOD2 NM_022162.3(NOD2):c.2817T>C (p.Ile939=)SNV Conflicting interpretations of pathogenicity 97868 rs104895454 16:50757230-50757230 16:50723319-50723319
26 NOD2 NM_022162.3(NOD2):c.413G>A (p.Arg138Gln)SNV Conflicting interpretations of pathogenicity 97877 rs104895456 16:50733738-50733738 16:50699827-50699827
27 NOD2 NM_022162.3(NOD2):c.703C>T (p.Arg235Cys)SNV Conflicting interpretations of pathogenicity 97879 rs104895422 16:50744525-50744525 16:50710614-50710614
28 NOD2 NM_022162.3(NOD2):c.74-7T>ASNV Conflicting interpretations of pathogenicity 97880 rs104895421 16:50733392-50733392 16:50699481-50699481
29 NOD2 NM_022162.3(NOD2):c.881C>G (p.Thr294Ser)SNV Conflicting interpretations of pathogenicity 97883 rs104895425 16:50744703-50744703 16:50710792-50710792
30 NOD2 NM_022162.3(NOD2):c.931C>T (p.Arg311Trp)SNV Conflicting interpretations of pathogenicity 97885 rs104895427 16:50744753-50744753 16:50710842-50710842
31 NOD2 NM_022162.3(NOD2):c.*8G>ASNV Conflicting interpretations of pathogenicity 103114 rs199475923 16:50765738-50765738 16:50731827-50731827
32 NOD2 NM_022162.3(NOD2):c.2107C>T (p.Arg703Cys)SNV Conflicting interpretations of pathogenicity 197333 rs5743277 16:50745929-50745929 16:50712018-50712018
33 NOD2 NM_022162.3(NOD2):c.484G>A (p.Val162Ile)SNV Conflicting interpretations of pathogenicity 319427 rs139571975 16:50733809-50733809 16:50699898-50699898
34 NOD2 NM_022162.3(NOD2):c.633C>T (p.Ala211=)SNV Conflicting interpretations of pathogenicity 319432 rs5743269 16:50741858-50741858 16:50707947-50707947
35 NOD2 NM_022162.3(NOD2):c.807G>A (p.Pro269=)SNV Conflicting interpretations of pathogenicity 319436 rs369766454 16:50744629-50744629 16:50710718-50710718
36 NOD2 NM_022162.3(NOD2):c.1981G>C (p.Ala661Pro)SNV Conflicting interpretations of pathogenicity 319455 rs369957746 16:50745803-50745803 16:50711892-50711892
37 NOD2 NM_022162.3(NOD2):c.2489G>A (p.Arg830Gln)SNV Conflicting interpretations of pathogenicity 319467 rs770915641 16:50750524-50750524 16:50716613-50716613
38 NOD2 NM_022162.3(NOD2):c.274G>A (p.Val92Ile)SNV Conflicting interpretations of pathogenicity 319425 rs187264529 16:50733599-50733599 16:50699688-50699688
39 NOD2 NM_022162.3(NOD2):c.460G>A (p.Asp154Asn)SNV Conflicting interpretations of pathogenicity 319426 rs146054564 16:50733785-50733785 16:50699874-50699874
40 NOD2 NM_022162.3(NOD2):c.531G>A (p.Pro177=)SNV Conflicting interpretations of pathogenicity 319428 rs775281342 16:50733856-50733856 16:50699945-50699945
41 NOD2 NM_022162.3(NOD2):c.859C>T (p.His287Tyr)SNV Conflicting interpretations of pathogenicity 319439 rs560242309 16:50744681-50744681 16:50710770-50710770
42 NOD2 NM_022162.3(NOD2):c.875C>T (p.Ala292Val)SNV Conflicting interpretations of pathogenicity 319441 rs149338478 16:50744697-50744697 16:50710786-50710786
43 NOD2 NM_022162.3(NOD2):c.2546C>T (p.Ala849Val)SNV Conflicting interpretations of pathogenicity 97855 rs104895486 16:50750581-50750581 16:50716670-50716670
44 NOD2 NM_022162.3(NOD2):c.2147G>A (p.Arg716His)SNV Conflicting interpretations of pathogenicity 319460 rs200035357 16:50745969-50745969 16:50712058-50712058
45 NOD2 NM_022162.3(NOD2):c.*89C>TSNV Conflicting interpretations of pathogenicity 319476 rs184545855 16:50765819-50765819 16:50731908-50731908
46 NOD2 NM_022162.3(NOD2):c.2463-9T>ASNV Conflicting interpretations of pathogenicity 319466 rs201759367 16:50750489-50750489 16:50716578-50716578
47 NOD2 NM_022162.3(NOD2):c.*873C>TSNV Conflicting interpretations of pathogenicity 319488 rs373812846 16:50766603-50766603 16:50732692-50732692
48 NOD2 NM_022162.3(NOD2):c.566C>T (p.Thr189Met)SNV Conflicting interpretations of pathogenicity 319431 rs61755182 16:50741791-50741791 16:50707880-50707880
49 NOD2 NM_022162.3(NOD2):c.1634C>T (p.Pro545Leu)SNV Conflicting interpretations of pathogenicity 319448 rs777949388 16:50745456-50745456 16:50711545-50711545
50 NOD2 NM_022162.3(NOD2):c.1839C>T (p.Phe613=)SNV Conflicting interpretations of pathogenicity 319453 rs149870902 16:50745661-50745661 16:50711750-50711750

UniProtKB/Swiss-Prot genetic disease variations for Inflammatory Bowel Disease 1:

73
# Symbol AA change Variation ID SNP ID
1 NOD2 p.Arg702Trp VAR_012689 rs2066844
2 NOD2 p.Gly908Arg VAR_012701 rs2066845

Expression for Inflammatory Bowel Disease 1

Search GEO for disease gene expression data for Inflammatory Bowel Disease 1.

Pathways for Inflammatory Bowel Disease 1

Pathways related to Inflammatory Bowel Disease 1 according to KEGG:

36
# Name Kegg Source Accession
1 NOD-like receptor signaling pathway hsa04621
2 Cytokine-cytokine receptor interaction hsa04060
3 JAK-STAT signaling pathway hsa04630
4 Inflammatory bowel disease (IBD) hsa05321
5 Autophagy - animal hsa04140

Pathways related to Inflammatory Bowel Disease 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.21 RIPK2 NOD2 NOD1 IL6
2 11.94 RIPK2 PRKCQ NOD1 ATG16L1
3
Show member pathways
11.6 RIPK2 NOD2 NOD1
4 11.52 TNFSF15 IL6 ATG16L1
5 11.28 RIPK2 NOD2 NOD1 IL6 ATG16L1
6 10.94 RIPK2 NOD2 NOD1
7 10.7 RIPK2 NOD2 NOD1

GO Terms for Inflammatory Bowel Disease 1

Biological processes related to Inflammatory Bowel Disease 1 according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.09 RIPK2 PRKCQ NOD2 NOD1 IRGM IL23R
2 innate immune response GO:0045087 10.05 RIPK2 NOD2 NOD1 IRGM IL23R
3 regulation of apoptotic process GO:0042981 9.94 RIPK2 NOD2 NOD1 DLG5
4 cellular response to lipopolysaccharide GO:0071222 9.88 RIPK2 NOD2 IRGM IL6
5 inflammatory response GO:0006954 9.85 RIPK2 PRKCQ NOD1 IRGM IL6 IL23R
6 defense response to Gram-positive bacterium GO:0050830 9.83 RIPK2 NOD1 IL6
7 interleukin-1-mediated signaling pathway GO:0070498 9.82 RIPK2 NOD2 NOD1
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 RIPK2 IRGM IL6
9 defense response to Gram-negative bacterium GO:0050829 9.81 IRGM IL6 IL23R
10 positive regulation of JNK cascade GO:0046330 9.8 RIPK2 NOD2 NOD1
11 positive regulation of T cell proliferation GO:0042102 9.78 PRKCQ IL6 IL23R
12 positive regulation of tumor necrosis factor production GO:0032760 9.73 RIPK2 NOD2 NOD1
13 JNK cascade GO:0007254 9.72 RIPK2 NOD2 NOD1
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.65 RIPK2 PRKCQ NOD2 NOD1 IL6
15 detection of bacterium GO:0016045 9.63 NOD2 NOD1
16 positive regulation of T-helper 1 type immune response GO:0002827 9.62 RIPK2 IL23R
17 nucleotide-binding oligomerization domain containing signaling pathway GO:0070423 9.61 RIPK2 NOD2 NOD1
18 positive regulation of T-helper 17 type immune response GO:2000318 9.6 PRKCQ IL23R
19 cellular response to peptidoglycan GO:0071224 9.59 RIPK2 NOD2
20 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.58 NOD2 NOD1
21 positive regulation of stress-activated MAPK cascade GO:0032874 9.58 RIPK2 NOD2 NOD1
22 positive regulation of xenophagy GO:1904417 9.57 RIPK2 NOD1
23 carnitine transport GO:0015879 9.54 SLC22A5 SLC22A4
24 protein lipidation involved in autophagosome assembly GO:0061739 9.52 IRGM ATG16L1
25 quaternary ammonium group transport GO:0015697 9.51 SLC22A5 SLC22A4
26 positive regulation of interleukin-17 production GO:0032740 9.5 PRKCQ NOD2 IL23R
27 pattern recognition receptor signaling pathway GO:0002221 9.49 NOD2 NOD1
28 carnitine transmembrane transport GO:1902603 9.48 SLC22A5 SLC22A4
29 detection of biotic stimulus GO:0009595 9.46 NOD2 NOD1
30 positive regulation of interleukin-6 production GO:0032755 9.46 RIPK2 NOD2 NOD1 IL6
31 cellular response to muramyl dipeptide GO:0071225 9.13 RIPK2 NOD2 NOD1
32 nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070431 8.8 RIPK2 NOD2 IRGM

Molecular functions related to Inflammatory Bowel Disease 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.91 SLC22A5 SLC22A4 RIPK2 PRKCQ NOD2 NOD1
2 nucleotide binding GO:0000166 9.86 SLC22A5 SLC22A4 RIPK2 PRKCQ NOD2 NOD1
3 peptidoglycan binding GO:0042834 9.4 NOD2 NOD1
4 pattern recognition receptor activity GO:0038187 9.32 NOD2 NOD1
5 quaternary ammonium group transmembrane transporter activity GO:0015651 9.16 SLC22A5 SLC22A4
6 carnitine transmembrane transporter activity GO:0015226 8.96 SLC22A5 SLC22A4
7 CARD domain binding GO:0050700 8.92 RIPK2 NOD2 NOD1 IRGM

Sources for Inflammatory Bowel Disease 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....